The University of Pennsylvania School of Nursing
Last Modified: December 13, 2011
What are the statistics of 10-year survival of Arimidex based on? Low risk breast cancer patients having lumpectomies? Single mastectomies? Bilateral mastectomies? Locations of tumors? etc. What were the circumstances in the studies and are they all lumped together when arriving at the statistics of improving odds from 85% to 91%?
Kevin Fox, MD, Medical Oncologist at Penn , responds:
The 10-year survival for low risk patients taking arimdex is excellent, and probably exceeds 95%. The figure is regardless of tumor location or type of surgery, so tumor location and type of operation don't matter. The figures you quote were derived from a study, which included patients with high risk breast cancers as well, so the overall figures are worse than what they are for you or for patients with low risk cancers.
This question and answer was part of the OncoLink Brown Bag Chat. Series, View the Life After Breast Cancer transcript.
Sep 29, 2010 - The T-cell leukemia 1A gene appears to be associated with musculoskeletal adverse events in women undergoing treatment with aromatase inhibitors for early-stage breast cancer, according to a study published online Sept. 27 in the Journal of Clinical Oncology.
Sep 29, 2010
Aug 21, 2014